Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis
Authors:
Open Access
- 21 January 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (1) , e0262931
Abstract
SHP2 is a latent biomarker for predicting the survivals of solid tumors. However, the current researches were controversial. Therefore, a meta-analysis is necessary to assess the prognosis of SHP2 on tumor patients. Searched in PubMed, EMBASE and web of science databases for published studies until Jun 20, 2021. A meta-analysis was performed to evaluate the affect of SHP2 in clinical stages, disease-free survival (DFS) and overall survival (OS) in tumor patients. This study showed that the expression of SHP2 had no significant correlation with clinical stages (OR: 0.91; 95% CI, 0.60–1.38; P = 0.65), DFS (HR = 0.88; 95%CI: 0.58–1.34; P = 0.56) and OS (HR = 1.07, 95%CI: 0.79–1.45, P = 0.67), but the prognostic effect varied greatly with tumor sites. High SHP2 expression was positively related to early clinical stage in hepatocellular carcinoma, not associated with clinical stage in the most of solid tumors, containing laryngeal carcinoma, pancreatic carcinoma and gastric carcinoma, etc. Higher expression of SHP2 could predict longer DFS in colorectal carcinoma, while predict shorter DFS in hepatocellular carcinoma. No significant difference was observed in DFS for non-small cell lung carcinoma and thyroid carcinoma. Higher SHP2 expression was distinctly related to shorter OS in pancreatic carcinoma and laryngeal carcinoma. The OS of the other solid tumors was not significantly different. The prognostic value of SHP2 might not equivalent in different tumors. The prognostic effect of SHP2 is highly influenced by tumor sites.Keywords
This publication has 32 references indexed in Scilit:
- The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2012
- RETRACTED ARTICLE: Dynamin 2 mediates PDGFRα-SHP-2-promoted glioblastoma growth and invasionOncogene, 2011
- Kit-Shp2-Kit signaling acts to maintain a functional hematopoietic stem and progenitor cell poolBlood, 2011
- Ptpn11/Shp2 Acts as a Tumor Suppressor in Hepatocellular CarcinogenesisCancer Cell, 2011
- A germline gain-of-function mutation in Ptpn11 (Shp-2) phosphatase induces myeloproliferative disease by aberrant activation of hematopoietic stem cellsBlood, 2010
- Overexpression of Protein Phosphatase Non-receptor Type 11 (PTPN11) in Gastric CarcinomasDigestive Diseases and Sciences, 2009
- Isolation of a distinct class of gain-of-function SHP-2 mutants with oncogenic RAS-like transforming activity from solid tumorsOncogene, 2008
- Practical methods for incorporating summary time-to-event data into meta-analysisTrials, 2007
- Laryngeal Cancer in the United States: Changes in Demographics, Patterns of Care, and SurvivalThe Laryngoscope, 2006
- Diverse Biochemical Properties of Shp2 MutantsJournal of Biological Chemistry, 2005